Literature DB >> 17307461

Are Marfan syndrome and marfanoid patients distinguishable on long-term follow-up?

Lars G Svensson1, Eugene H Blackstone, Jingyuan Feng, Daniel de Oliveira, A Marc Gillinov, Maran Thamilarasan, Richard A Grimm, Brian Griffin, Donald Hammer, Timothy Williams, Deborah H Gladish, Bruce W Lytle.   

Abstract

BACKGROUND: It is unclear whether late outcome differs for Marfan syndrome and marfanoid patients. Thus, we compared characteristics of Marfan versus marfanoid patients and their survival and requirement for reoperation.
METHODS: From 1978 to October 2003, 162 patients with a presumptive diagnosis of Marfan syndrome underwent operation. We recategorized them as confirmed Marfan (n = 122), marfanoid (n = 23), Ehlers-Danlos syndrome (n = 5), or other (n = 12). Patients categorized as marfanoid failed to meet the major criteria of Marfan syndrome. We compared characteristics of Marfan and marfanoid groups and assessed long-term survival and need for reoperation.
RESULTS: Marfan and marfanoid patients had similar demographics (women, 33% versus 39%; age, 39 +/- 13 versus 41 +/- 12 years; height, 186 +/- 12 cm versus 184 +/- 9.6 cm), valve pathophysiology (aortic regurgitation, 66% versus 58%; mitral regurgitation, 58% versus 62%), and aortic pathology (dilated, 40% versus 39%; dissected, 17% versus 13%). Overall hospital survival was 99.3% (144/145), and 10-year survival was similar at 82% in the Marfan and 100% in marfanoid groups (p = 0.13). Patients with aortic dissection (p = 0.001) and mitral valve replacement (p = 0.003) were at higher risk of death. Reoperation was more frequent after separate aortic valve-ascending aorta graft operations (p = 0.04), and among taller patients (p = 0.005). Of 24 Marfan patients with David root reimplantations, none has required reoperation.
CONCLUSIONS: Marfan and marfanoid patients have similar physical characteristics and postoperative survival, although reoperation was more frequent in Marfan patients. Surgery before occurrence of aortic dissection or mitral valve repair should reduce the risk of reoperation, but taller patients, irrespective of Marfan or gender, are more likely to require reoperation.

Entities:  

Mesh:

Year:  2007        PMID: 17307461     DOI: 10.1016/j.athoracsur.2006.10.062

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  5 in total

1.  Report of the National Heart, Lung, and Blood Institute and National Marfan Foundation Working Group on research in Marfan syndrome and related disorders.

Authors:  Gail D Pearson; Richard Devereux; Bart Loeys; Cheryl Maslen; Dianna Milewicz; Reed Pyeritz; Francesco Ramirez; Daniel Rifkin; Lynn Sakai; Lars Svensson; Andy Wessels; Jennifer Van Eyk; Harry C Dietz
Journal:  Circulation       Date:  2008-08-12       Impact factor: 29.690

2.  Pregnancy and Marfan syndrome.

Authors:  Sorel Goland; Uri Elkayam
Journal:  Ann Cardiothorac Surg       Date:  2017-11

3.  Long-term survival, valve durability, and reoperation for 4 aortic root procedures combined with ascending aorta replacement.

Authors:  Lars G Svensson; Saila T Pillai; Jeevanantham Rajeswaran; Milind Y Desai; Brian Griffin; Richard Grimm; Donald F Hammer; Maran Thamilarasan; Eric E Roselli; Gösta B Pettersson; A Marc Gillinov; Jose L Navia; Nicholas G Smedira; Joseph F Sabik; Bruce W Lytle; Eugene H Blackstone
Journal:  J Thorac Cardiovasc Surg       Date:  2015-11-10       Impact factor: 5.209

4.  Commentary: reimplantation versus root remodelling for connective tissue disorder patients.

Authors:  Lars G Svensson
Journal:  Eur J Cardiothorac Surg       Date:  2022-08-03       Impact factor: 4.534

5.  Reply: For connective disease root aneurysms, reimplantation is the best option.

Authors:  Lars G Svensson
Journal:  JTCVS Open       Date:  2021-08-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.